#biopharmaceuticals #Fosun International #Guo Guangchang

Aiming for Excellence: Fosun's Path to Global Leadership

On August 29, 2025, during the interim results presentation held in Shanghai, Guo Guangchang, Chairman of Fosun International, articulated the company’s strategic ambitions to reinforce its position in the biopharmaceutical sector. This announcement underlined Fosun's commitment to investing in advantageous industries and its goal of becoming a global leader.

The presentation was attended by key figures, including Fosun’s Co-Chairman Wang Qunbin, Co-CEOs Chen Qiyu and Xu Xiaoliang, CFO Gong Ping, and various investors and analysts. Guo emphasized notable accomplishments achieved by Fosun within multiple sectors throughout the first half of 2025, especially in biopharmaceuticals, which reflect the company's ongoing growth trajectory.

As Fosun pivots towards new opportunities, Guo specifically highlighted the company’s robust pipeline of innovative drugs. Addressing investor concerns surrounding research and development (R&D), he assured that Fosun is well-prepared with a pipeline of crucial products. This includes developments powered by Henlius and Fosun Kite's CAR-T therapy. Guo underscored the importance of not merely licensing out these innovations but rather advancing R&D to produce world-class products, thereby underscoring a long-term strategic perspective.

Additionally, Guo elucidated Fosun's vision for healthcare, aiming to promote longevity where individuals can live healthy lives up to 121 years. He noted that advancements in cancer treatment are on the rise, making diseases that were once deemed terminal increasingly manageable and treatable, and he believes that cancer should ultimately be curable.

According to him, the future of cancer treatment will not rely solely on single modalities; rather, it will involve a comprehensive approach combining pharmacological interventions, innovative devices, and multi-drug therapies. With Fosun’s extensive strategic layout and industry-wide presence in the health sector, Guo sees the company uniquely positioned to navigate and innovate within this evolving frontier of healthcare.

One distinguishing factor for Fosun is its unwavering commitment to establishing global R&D, clinical, and sales capabilities. Guo reiterated that this multifaceted approach is essential for Fosun’s pursuit of excellence and its ambition of becoming a globally recognized pharmaceutical leader.

Sharing insights on the importance of sustained investment, Guo noted that establishing a competitive advantage demands relentless effort over many years. Highlighting the example of Henlius, which has undergone over a decade of investment exceeding RMB10 billion without immediate results, he emphasized the significance of long-term planning and perseverance. Similarly, Fosun's insurance branches are now realizing profitability after years of development.

Fosun’s current excitement lies not in exploration of entirely new ventures, but rather in cultivating and enhancing its existing industries where it has developed significant advantages. The aim is to effectuate breakthroughs, stimulate growth, and achieve a paramount status within established sectors.

In a recent innovation, Fosun’s Shede Spirits has rolled out a new liquor product,